GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

@inproceedings{NoyanAshraf2009GLP1RAL,
  title={GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice},
  author={Mohammad Hossein Noyan-Ashraf and M. Abdul Momen and Kiwon Ban and Al-Muktafi Sadi and Yu-qing Zhou and A. Mehdi Riazi and Laurie L. Baggio and R. Mark Henkelman and Mansoor Husain and Daniel J Drucker},
  booktitle={Diabetes},
  year={2009}
}
OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear. RESEARCH DESIGN AND METHODS We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS